“And so we think mid-single-digit plus from today's point of view, for the base business is the right way to think about it.”

In context

“obviously, you see a lot of mixed signals on the macro. Last call, you had suggested all-in organic mid-single and if you factor in the COVID would roll off low single digits, like any updated thinking on how you think about that? I know you've already addressed the bioprocess side, but just wondering for the other parts of the business, kind of how those are playing out right now? Rainer Blair: Thanks, Dan. So, I think we are still in that ZIP code here, specifically, if we think about our base business without testing, so our business without COVID testing. For 2023, we still see that as mid-single-digit plus. And of course, we're watching. There's a lot of headlines in Western Europe and emerging markets, but to date, our business momentum does not indicate any dramatic slowdown here. And so we think mid-single-digit plus from today's point of view, for the base business is the right way to think about it. And as we go forward here and Matt mentioned this, of course, we're looking at all the data points daily here. And then in January, we'll update you again, but from today's perspective, mid-single-digit plus for the base business. And then as it relates to COVID testing, we do still anticipate that step down, the experts that we speak with, our customers still think that COVID is endemic by the end of '23, beginning of '24 and that will step down there from where we've been here, close to 50 million tests to about 30 million tests or the $1.2 billion roughly of COVID revenue. And then lastly, I'll say, the FX situation is very dynamic. We've been talking about that. And I think Matt covered that as well. Dan Brennan: Great. And then just maybe one more follow-up. I don't want to kind of c”